References
- Samim D, Choffat D, Vollenweider P, Waeber G, Marques-Vidal P, Méan M. Prevalence of atrial fibrillation: the Swiss population-based CoLaus|PsyCoLaus study. Herz. 2023; 48:48–54.
- Perino AC, Kaiser DW, Lee RJ, Fan J, Askari M, Schmitt SK, et al. Incidence and outcomes of patients with atrial fibrillation and major bleeding complications: from the TREAT-AF study. J Interv Card Electrophysiol. 2021; 62:133–42.
- Migdady I, Russman A, Buletko AB. Atrial fibrillation and ischemic stroke: a clinical review. Semin Neurol. 2021; 41:348–64.
- Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, et al. Stroke prevention in patients with atrial fibrillation: a systematic review update. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018. Report No.: AHRQ 18-EHC018-EFReport No.: PCORI® 2018-SR-04.
- Franco Moreno AI, Martín Díaz RM, García Navarro MJ. Direct oral anticoagulants: an update. Med Clin (Barc). 2018; 151:198–206.
- Chan N, Hirsh J. Unresolved issues in the use of direct acting oral anticoagulants. Expert Rev Cardiovasc Ther. 2023; 21:913–21.
- Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016; 388:806–17.
- van Miert JHA, Bos S, Veeger NJGM, Meijer K. Clinical usefulness of the SAMe-TT2R2 score: a systematic review and simulationmeta-analysis. PLoS One. 2018; 13:e0194208. doi: 10.1371/journal. pone.0194208
- Reiffel JA. Time to revisit the time in the therapeutic range. J Atr Fibrillation. 2017; 9:1569. doi: 10.4022/jafib.1569
- Methavigul K, Krittayaphong R. The novel risk score model for predicting the poor anticoagulation control in patients with atrial fibrillation taking warfarin. Asian Biomed (Res Rev News). 2025; 19:106–13.